A Phase IB Study Of The BTKi CC-292 Combined With Lenalidomide In Adults Patients With Relapsed/Refractory B-Cell Lymphoma — CLEAR

Relapsed/Refractory B-cell Lymphoma Clinical Trial

Official title:
A PHASE IB STUDY OF THE BTKi CC-292 COMBINED WITH LENALIDOMIDE IN ADULTS PATIENTS WITH RELAPSED/REFRACTORY B-CELL LYMPHOMA

Status Completed

Clinical Trial Summary

This is an open label, 3 + 3 dose escalation study, to determine the MTD, safety, efficacy and PK profiles for subjects with relapsed/refractory B-cell malignancies when using CC-292 and lenalidomide combination therapy. Subjects will be followed for disease progression and collection of second primary malignancy (SPM) events. This dose escalation will be followed by an exploratory expansion phase in 3 cohorts of 12 patients each.

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Lymphoma
Lymphoma, B-Cell
Relapsed/Refractory B-cell Lymphoma

Clinical Trial Details

NCT number	NCT01766583
Study type	Interventional
Source	The Lymphoma Academic Research Organisation
Contact
Status	Completed
Phase	Phase 1
Start date	February 2013
Completion date	January 2018

View Details

See also
Status	Clinical Trial	Phase
Recruiting	`NCT05950334` - FT522 With Rituximab in Relapsed/Refractory B-Cell Lymphoma (FT522-101)	Phase 1
Active, not recruiting	`NCT03156101` - A Clinical Study Evaluating the Safety and Efficacy of BinD19 Treatment in R/R ALL and Lymphoma Subjects	Phase 1/Phase 2
Recruiting	`NCT06445517` - Study Evaluating ISM8207 in Participants With Advanced Solid Tumors and Relapsed/Refractory B-Cell Lymphoma	Phase 1